<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043550</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH061410</org_study_id>
    <secondary_id>R01MH061410</secondary_id>
    <secondary_id>DSIR 83-ATAS</secondary_id>
    <nct_id>NCT00043550</nct_id>
  </id_info>
  <brief_title>Treatments for Depression: Drug Versus Psychotherapy</brief_title>
  <official_title>Efficacy of Dynamic Therapy Versus Selective Serotonin Reuptake Inhibitor for Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 4-8 month study, with a 2-year follow up period, will compare sertraline (Zoloft®),
      venlafaxine (Effexor®), supportive-expressive psychotherapy, and placebo to determine which
      is more effective in treating major depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MDD is one of the most prevalent psychiatric disorders. Different forms of psychotherapy for
      depression have been found effective. This study compares a form of dynamic psychotherapy
      called supportive-expressive psychotherapy to medication and to placebo.

      Participants are evaluated on 2 occasions, 1 week apart, before they are randomly assigned to
      receive either supportive-expressive psychotherapy, sertraline (Zoloft) (followed by
      venlafaxine [Effexor] if patients do not respond to sertraline), or placebo. The active phase
      of treatment lasts 4 months. The frequency of patients' visits depends on the assigned
      treatment.

      Patients who are randomized to receive medication or placebo are initially seen on a weekly
      basis, then less often, depending on the rate of symptomatic improvement. Patients who are
      randomized to psychotherapy are seen twice a week for the first 4 weeks, then once a week for
      the remaining 12 weeks. Outcome is monitored at week 2,4,6,7,8, 12, 15 and 16. At the end of
      the first 16 weeks of treatment, patients are thoroughly evaluated. Those who have responded
      to treatment are assigned to a continuation phase and are seen once a month for another 16
      weeks. At the end of the 16-week continuation phase, patients are again evaluated and all
      treatments are stopped. Follow-up continues every 3 months for up to 2 years to ensure that
      the patients' depression remains under control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression-17 Item</measure>
    <time_frame>symptoms assessed during past 7 days, measure taken at baseline, week 8 and week 16</time_frame>
    <description>Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1960). We used the 17-item version of the 27-item HRSD, a measure of depression severity. The Structured Interview Guide was used to conduct the interviews (SIGH-D; Williams, 1988). The reliability and validity of the HRSD are well documented (Rabkin &amp; Klein, 1987). Interjudge reliability as assessed by interclass correlations was .92 in our sample. Total 17-item scores could range from 17-48 with higher scores indicating greater distress.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>1 Sertraline/Venlafaxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive sertraline for the first 8 weeks. Participants will receive venlafaxine if they do not respond to sertraline by week 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Supportive Expressive Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive supportive-expressive psychotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Pill Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Supportive Expressive Therapy</intervention_name>
    <description>The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.</description>
    <arm_group_label>2 Supportive Expressive Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Participants will receive sertraline.</description>
    <arm_group_label>1 Sertraline/Venlafaxine</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pill Placebo</intervention_name>
    <description>Participants will receive a pill placebo.</description>
    <arm_group_label>3 Pill Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Participants will receive venlafaxine.</description>
    <arm_group_label>1 Sertraline/Venlafaxine</arm_group_label>
    <other_name>Effexor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Major Depressive Disorder diagnosis

        Exclusion criteria:

          -  Psychotic or bipolar disorder diagnosis

          -  Substance dependence in the last 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Barber, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Barber JP, Muenz LR. The role of avoidance and obsessiveness in matching patients to cognitive and interpersonal psychotherapy: empirical findings from the treatment for depression collaborative research program. J Consult Clin Psychol. 1996 Oct;64(5):951-8.</citation>
    <PMID>8916624</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2002</study_first_submitted>
  <study_first_submitted_qc>August 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2002</study_first_posted>
  <results_first_submitted>August 26, 2015</results_first_submitted>
  <results_first_submitted_qc>April 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2017</results_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>374 individuals, ages 18 to 70 years, were recruited through advertisements on public transportation, free news publications, area physicians, and outpatient clinics during the period of 2001-2006.</recruitment_details>
      <pre_assignment_details>Individuals not meeting MDD diagnostic criteria11 using the Structured Clinical Interviews for DSM-IV12 or scoring less than 14 on the 17-item Hamilton Rating Scale for Depression (HRSD)13,14 at two evaluations one week apart were excluded (n=88).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Sertraline</title>
          <description>Participants receive sertraline.
Sertraline : Participants will receive sertraline.</description>
        </group>
        <group group_id="P2">
          <title>2 Supportive-expressive Psychotherapy</title>
          <description>Participants will receive supportive-expressive psychotherapy.
Supportive Expressive Therapy : The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.</description>
        </group>
        <group group_id="P3">
          <title>3 Pill Placebo</title>
          <description>Participants receive placebo.
Pill Placebo : Participants will receive a pill placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 8 Completed</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1 Sertraline</title>
          <description>Participants receive sertraline.
Sertraline : Participants will receive sertraline.</description>
        </group>
        <group group_id="B2">
          <title>2 Supportive-expressive Psychotherapy</title>
          <description>Participants will receive supportive-expressive psychotherapy.
Supportive Expressive Therapy : The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.</description>
        </group>
        <group group_id="B3">
          <title>3 Pill Placebo</title>
          <description>Participants receive placebo.
Pill Placebo : Participants will receive a pill placebo.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="156"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.0" spread="12.5"/>
                    <measurement group_id="B2" value="36.2" spread="12.2"/>
                    <measurement group_id="B3" value="38.3" spread="12.0"/>
                    <measurement group_id="B4" value="37.5" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Rating Scale for Depression-17 Item</title>
        <description>Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1960). We used the 17-item version of the 27-item HRSD, a measure of depression severity. The Structured Interview Guide was used to conduct the interviews (SIGH-D; Williams, 1988). The reliability and validity of the HRSD are well documented (Rabkin &amp; Klein, 1987). Interjudge reliability as assessed by interclass correlations was .92 in our sample. Total 17-item scores could range from 17-48 with higher scores indicating greater distress.</description>
        <time_frame>symptoms assessed during past 7 days, measure taken at baseline, week 8 and week 16</time_frame>
        <population>Numbers vary from consented due to dropout prior to start of study. 156 patients consented and randomized. 11 patients did not complete at least one post-randomization measure and were therefore not included in these analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Sertraline</title>
            <description>Participants receive sertraline.
Sertraline : Participants will receive sertraline.</description>
          </group>
          <group group_id="O2">
            <title>2 Supportive-expressive Psychotherapy</title>
            <description>Participants will receive supportive-expressive psychotherapy.
Supportive Expressive Therapy : The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.</description>
          </group>
          <group group_id="O3">
            <title>3 Pill Placebo</title>
            <description>Participants receive placebo.
Pill Placebo : Participants will receive a pill placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Rating Scale for Depression-17 Item</title>
          <description>Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1960). We used the 17-item version of the 27-item HRSD, a measure of depression severity. The Structured Interview Guide was used to conduct the interviews (SIGH-D; Williams, 1988). The reliability and validity of the HRSD are well documented (Rabkin &amp; Klein, 1987). Interjudge reliability as assessed by interclass correlations was .92 in our sample. Total 17-item scores could range from 17-48 with higher scores indicating greater distress.</description>
          <population>Numbers vary from consented due to dropout prior to start of study. 156 patients consented and randomized. 11 patients did not complete at least one post-randomization measure and were therefore not included in these analyses.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Initial HRSD-17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="3.4"/>
                    <measurement group_id="O2" value="19.9" spread="3.9"/>
                    <measurement group_id="O3" value="19.4" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid-treatment HRSD-17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="7.2"/>
                    <measurement group_id="O2" value="12.5" spread="6.9"/>
                    <measurement group_id="O3" value="12.7" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOCF HRSD-17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="7.6"/>
                    <measurement group_id="O2" value="14.5" spread="8.3"/>
                    <measurement group_id="O3" value="14.3" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison of conditions</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The proposed sample size had at least 80% power to detect effect sizes of 0.36 between the two active treatment conditions and placebo during the active phase. These power calculations were based on a priori values of within-subject correlation of 0.50, 10% attrition, and 6 assessment points.</non_inferiority_desc>
            <p_value>.95</p_value>
            <p_value_desc>Overall significant effect for treatment, as well as the two moderating effects, used a Bonferroni-corrected alpha level of 0.0167 (0.05/3).</p_value_desc>
            <method>HLM</method>
            <param_type>Slope</param_type>
            <param_value>1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>effects of conditions over time</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>HLM</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.35</ci_lower_limit>
            <ci_upper_limit>.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.33</ci_lower_limit>
            <ci_upper_limit>.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 Sertraline</title>
          <description>Participants receive sertraline.
Sertraline : Participants will receive sertraline.</description>
        </group>
        <group group_id="E2">
          <title>2 Supportive-expressive Psychotherapy</title>
          <description>Participants will receive supportive-expressive psychotherapy.
Supportive Expressive Therapy : The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.</description>
        </group>
        <group group_id="E3">
          <title>3 Pill Placebo</title>
          <description>Participants receive placebo.
Pill Placebo : Participants will receive a pill placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>passive suicide attempt</sub_title>
                <description>patient reported taking 4.5 mg of alprazolam . An hour later he took venlafaxine 187.5 mg, methylphenidate 30mg, and oxycodone 5mg with acetominophen. Patient was taken to the hospital ER and released without medical intervention.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Two limitations are the relatively high level of attrition and small sample size for specific combinations within our moderation analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jacques P.Barber, PhD, Dean and Professor</name_or_title>
      <organization>Adelphi University, The Derner Institute of Advanced Psychological Studies</organization>
      <phone>516.877.4807</phone>
      <email>jbarber@adelphi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

